최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국호스피스·완화의료학회지 = Korean journal of hospice and palliative care, v.18 no.1, 2015년, pp.1 - 8
서민석 (연세대학교 의과대학 강남세브란스병원 가정의학과) , 심재용 (연세대학교 대학원 의학과)
Breakthrough cancer pain is a transient exacerbation of pain that occurs despite relatively well controlled background pain with around-the-clock analgesia. It is highly prevalent in patients with cancer pain, with an overall prevalence of 70~90%. Breakthrough cancer pain has several negative effect...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
현재 가장 많이 인용되는 돌발성 통증의 정의는 무엇인가? | 현재 가장 많이 인용되는 돌발성 통증의 정의는 다음과 같다. “돌발성 통증은 기저 통증(background pain)이 충분히 조절됨에도 불구하고 자발적이거나(spontaneously), 예측 가능한 또는 예측 불가능한 유발요인(trigger)에 의해 일시적으로 악화되는 통증이다.”(11) Corli 등은 최근에 이탈리아 완화의료 전문가들의 대규모 조사를 바탕으로 개정된 돌발성 암성 통증의 정의를 제시하였으며, 이는 다음과 같다. | |
돌발성 통증의 특징은 무엇인가? | 돌발성 통증은 중증도 이상의 통증이 급성으로 발현 되어 짧은 기간 동안 지속되는 것이 특징이다. 여러 연구 결과에 따르면 통증은 5∼10분 이내에 최고조에 이르러 평균 30∼60분 정도 지속되었고, 매일 3∼4회 정도의 빈도를 보였다(13,14). | |
영국/아일랜드 완화의료 협회에서 제시한 권고안에서 돌발성 통증은 병태 생리학적 기전에 따라 어떻게 분류되는가? | 1) 특발성/자발성 통증(Idiopathic/Spontaneous pain): 확인할 수 있는 유발 요인이 없이 통증이 발생하여, 예측이 불가능한 통증 2) 사건 통증(Incident pain): 확인할 수 있는 유발 요인으로 인해 통증이 발생하여, 다소 예측이 가능한 통증 (1) 의지적 행동으로 인한 통증(Volitional incident pain): 걷기 (2) 비의지적 행동으로 인한 통증(Non-volitional incident pain): 기침, 구토 3) 시술에 의한 통증(Procedural pain): 상처소독 |
Foley KM. Acute and chronic cancer pain syndromes. In: Doyle D, Hanks G, Cherny N, Calman K, eds. Oxford textbook of palliative medicine. 3rd ed. New York:Oxford University Press; 2004. p. 298-316.
van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-49.
Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: a systematic review and pooled analysis of published literature. J Pain Symptom Manage 2014;47:57-76.
Hong SH, Roh SY, Kim SY, Shin SW, Kim CS, Choi JH, et al. Change in cancer pain management in Korea between 2001 and 2006: results of two nationwide surveys. J Pain Symptom Manage 2011;41:93-103.
Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-83.
Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002;3:38-44.
Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S; European Palliative Care Research Collaborative (EPCRC). Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain 2010;149:476-82.
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81.
Walsh D, Rivera NI, Davis MP, Lagman R, Legrand SB. Strategies for pain management: cleveland clinic foundation guidelines for opioid dosing for cancer pain. Support Cancer Ther 2004;1: 157-64.
Zucco F, Bonezzi C, Fornasari D. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy. Adv Ther 2014;31:657-82.
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G; Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8.
Corli C, Pizzuto M; OICP Research Group. Per qualche dolore in meno. Capire e trattare il breakthrough cancer pain. Roma: CIC Edizioni Internazionali;2011.
Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 2013;46:619-28.
Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 2010;6:97-108.
Hagen NA, Stiles C, Nekolaichuk C, Biondo P, Carlson LE, Fisher K, et al. The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews. J Pain Symptom Manage 2008; 35:136-52.
Sperlinga R, Campagna S, Berruti A, Laciura P, Ginosa I, Paoletti S, et al. Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain. Eur J Pain 2014 Nov 5. Epub 2014 Nov 5.
Fainsinger RL, Nekolaichuk C, Lawlor P, Hagen N, Bercovitch M, Fisch M, et al. An international multicentre validation study of a pain classification system for cancer patients. Eur J Cancer 2010;46:2896-904.
Caraceni A, Bertetto O, Labianca R, Maltoni M, Mercadante S, Varrassi G, et al. Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI--Italian questionnaire for intense episodic pain. J Pain Symptom Manage 2012;43:833-41.
Zeppetella G, Ribeiro MD. Episodic pain in patients with advanced cancer. Am J Hosp Palliat Care 2002;19:267-76.
Raj SX, Thronaes M, Brunelli C, Hjermstad MJ, Klepstad P, Kaasa S. A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. Support Care Cancer 2014;22:1965-71.
Breakthrough cancer pain survey fact sheet [Internet]. Baltimore: American Pain Foundation (US); 2010. Apr 26 [cited 2015 Jan 2]. Available from: http://www.harrisinteractive.com/vault/Client_News_AmericanPainFoundation_Fact_2010_01.pdf.
Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20:1420-33.
Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol 1997;24(5 Suppl 16): S16-7-12.
Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13:e58-68.
Hanks G. Oral transmucosal fentanyl citrate for the management of breakthrough pain. Eur J Palliat Care 2001;8:6-9.
Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev 2013;10:CD004311.
Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B. Consensus panel recommendations for the assessment and management of breakthrough pain: Part II - management. P&T 2005;30:354-61.
Davies AN. Breakthrough cancer pain. Curr Pain Headache Rep 2014;18:420.
Current state and improvement plan of cancer pain management: focused on opioid analgesics [Internet]. Seoul: National Evidence-based Healthcare Collaborating Agency; 2012. Dec 31 [cited 2015 Jan 8]. Available from: http://www.neca.re.kr/center/researcher/report_view.jsp?boardNoGA&seq71&q6 26f6172644e6f3d4741.
Bedard G, Davies A, McDonald R, Hawley P, Buchanan A, Popovic M, et al. Breakthrough cancer pain: a comparison of surveys with European and Canadian patients. Support Care Cancer 2015;23:791-6.
Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage 2013;46:573-80.
Bhatnagar S, Devi S, Vinod N, Jain P, Durgaprasad G, Maroo SH, et al. Safety and efficacy of oral transmucosal fentanyl citrate compared to morphine sulphate immediate release tablet in management of breakthrough cancer pain. Indian J Palliat Care 2014;20:182-7.
Darba J, Kaskens L, Sanchez-de la Rosa R. Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain. Clinicoecon Outcomes Res 2013;6:1-9.
Yamaguchi T, Shima Y, Morita T, Hosoya M, Matoba M; Japanese Society of Palliative Medicine. Clinical guideline for pharmacological management of cancer pain: the Japanese Society of Palliative Medicine recommendations. Jpn J Clin Oncol 2013;43:896-909.
Poulain P, Michenot N, Ammar D, Delorme C, Delorme T, Diquet B, et al. Mise au point sur l'utilisation du fentanyl transmuqueux: chez le patient presentant des douleurs d'origine canc?reuse. Douleurs Analg 2012;25:102-17.
NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain Version 2. [Internet]. Washington, PA: National Comprehensive Cancer Network (US); 2014. May 11 [cited 2014 Dec 29]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf.
Guidelines & protocols: palliative care for the patient with incurable cancer or advanced disease - Part 2: pain and symptom management [Internet]. Victoria, B.C.: British Columbia. Ministry of Health; 2011. Sep 30 [cited 2015 Jan 5]. Available from: http://www.bcguidelines.ca/guideline_ palliative2.html.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.